Clinical Trial

Weight and BMI Patterns in Biological Based IBD Patients and Its Finacial Impact

Study acronym: obesity/IFX
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Primary Objective To determine the pattern of weight and body mass index (BMI) changes in biologic-treated patients with inflammatory bowel disease (IBD). Secondary Objectives To evaluate the correlation between BMI and biologic drug dosing. To estimate the direct financial burden of biologic therapy according to BMI categories. To assess whether higher BMI is associated with increased treatment requirements.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-23.
Trial Details
NCT Number NCT07495800
Lead Sponsor Assiut University
Conditions Inflammatory Bowel Diseases Weight Changes
Enrollment 50 participants
Start Date 2026-05-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-30